STOCK TITAN

BridgeBio Pharma CEO reports sales of 54,980 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported selling 54,980 common shares on November 18 and 19, 2026, through direct transactions and the Kumar Haldea Family Irrevocable Trust, of which he is a co-trustee. The sales were made under a Rule 10b5-1 plan adopted May 13, 2026.

Separate indirect holdings as of November 18 included 750,000 shares held by NK 2026 GRAT and 3,568,447 held by Kumar Haldea Revocable Trust. Kumar disclaims beneficial ownership of those trust-held shares except to the extent of his pecuniary interest.

Insider Kumar Neil
Role Chief Executive Officer
Sold 54,980 shs ($4.28M)
Type Security Shares Price Value
Sale Common Stock F1, F5, F4 8,500 $78.3503 $666K
Sale Common Stock F1, F6, F4 1,500 $79.293 $119K
Sale Common Stock F1, F2 4,490 $76.9916 $346K
Sale Common Stock F1, F3 30,490 $77.8271 $2.37M
Sale Common Stock F1, F2, F4 1,277 $76.9915 $98K
Sale Common Stock F1, F3, F4 8,723 $77.8269 $679K
Holding Common Stock F7 -- -- --
Holding Common Stock F4 -- -- --
Holdings After Transaction: Common Stock — 243,327 shares (Direct); Common Stock — 475,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 750,000 shares (Indirect, By NK 2026 GRAT); Common Stock — 3,568,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.)
Footnotes (7)
  1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
  2. F2. Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  3. F3. Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  4. F4. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  5. F5. Represents the weighted average sale price of the shares sold from $78.00 to $78.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  6. F6. Represents the weighted average sale price of the shares sold from $79.04 to $79.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  7. F7. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Shares sold and weighted-average price 8,500 shares at $78.3503 per share Kumar Haldea Family Irrevocable Trust, November 19, 2026
Shares sold and weighted-average price 1,500 shares at $79.2930 per share Kumar Haldea Family Irrevocable Trust, November 19, 2026
Shares sold and weighted-average price 4,490 shares at $76.9916 per share Direct, November 18, 2026
Shares sold and weighted-average price 30,490 shares at $77.8271 per share Direct, November 18, 2026
Shares sold and weighted-average price 1,277 shares at $76.9915 per share Kumar Haldea Family Irrevocable Trust, November 18, 2026
Shares sold and weighted-average price 8,723 shares at $77.8269 per share Kumar Haldea Family Irrevocable Trust, November 18, 2026
Shares held by NK 2026 GRAT 750,000 shares Indirect holding reported as of November 18, 2026
Shares held by Kumar Haldea Revocable Trust 3,568,447 shares Indirect holding reported as of November 18, 2026
Rule 10b5-1 sales plan regulatory
"under a Rule 10b5-1 sales plan adopted by the Reporting Person"
weighted average sale price financial
"Represents the weighted average sale price of the shares sold"
grantor retained annuity trust financial
"a grantor retained annuity trust of which the Reporting Person is the sole trustee"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
beneficial ownership regulatory
"disclaims beneficial ownership of these shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBIO shares did Neil Kumar report selling?

Neil Kumar reported sales totaling 54,980 shares on November 18 and 19, 2026, through direct transactions and the Kumar Haldea Family Irrevocable Trust. The sales were made under a Rule 10b5-1 plan adopted May 13, 2026.

What were the prices of Neil Kumar's BBIO share sales?

On November 18, direct sales were 4,490 shares at a weighted-average $76.9916 per share and 30,490 at a weighted-average $77.8271. The Kumar Haldea Family Irrevocable Trust sold 1,277 shares at a weighted-average $76.9915 and 8,723 at $77.8269. On November 19, the trust sold 8,500 shares at $78.3503 and 1,500 at $79.2930 per share; each price was a weighted average.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kumar Neil

(Last)(First)(Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026S(1)4,490D$76.9916(2)273,817D
Common Stock11/18/2026S(1)30,490D$77.8271(3)243,327D
Common Stock11/18/2026S(1)1,277D$76.9915(2)494,409IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(4)
Common Stock11/18/2026S(1)8,723D$77.8269(3)485,686IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(4)
Common Stock11/19/2026S(1)8,500D$78.3503(5)477,186IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(4)
Common Stock11/19/2026S(1)1,500D$79.293(6)475,686IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(4)
Common Stock750,000IBy NK 2026 GRAT(7)
Common Stock3,568,447IBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
2. Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
4. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
5. Represents the weighted average sale price of the shares sold from $78.00 to $78.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
6. Represents the weighted average sale price of the shares sold from $79.04 to $79.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
7. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Remarks:
/s/ Will Solis, Attorney-in-Fact11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading